| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.3816/CBC.2005.N.014 |
| P698 | PubMed publication ID | 16001990 |
| P2093 | author name string | David H Gordon | |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase III clinical trial | Q42824827 |
| P304 | page(s) | 125-131 | |
| P577 | publication date | 2005-06-01 | |
| P1433 | published in | Clinical Breast Cancer | Q332245 |
| P1476 | title | Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials | |
| P478 | volume | 6 |
| Q36737426 | Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis. |
| Q34779398 | Current aproach to cancer pain management: Availability and implications of different treatment options. |
| Q41886663 | Effects of zoledronic acid and ibandronic acid on renal functions and calcium, phosphorus and alkaline phosphatase levels in breast cancer patients with bone metastases: a retrospective analysis |
| Q36985287 | Health resource utilization associated with skeletal-related events: results from a retrospective European study |
| Q38155649 | Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor |
| Q35583788 | Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. |
| Q36583753 | Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. |
| Q37699431 | Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo |
| Q38075447 | Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre |
Search more.